Esketamine Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Esketamine Market Growth Potential: How Will Market Size Shift Through 2030?
The esketamine market has seen substantial growth in recent years. The market is forecast to expand from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. Historically, this growth can be attributed to unmet needs in major depressive disorder, limitations of traditional antidepressants, regulatory approvals for nasal esketamine, rising mental health awareness, and the expansion of specialty psychiatric clinics.
The esketamine market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.6%. This expansion during the projection period stems from factors such as the rising incidence of treatment-resistant depression, a need for swift-acting treatments, the broader adoption of supervised outpatient delivery, an expanding mental health infrastructure, and ongoing investment in clinical research. Key developments anticipated within this timeframe involve the increasing uptake for treatment-resistant depression, the wider availability of nasal spray administration, greater utilization in acute psychiatric care environments, enhanced monitoring and regulated distribution, and intensified research efforts into rapid-acting antidepressants.
Get A Free Sample Report With In-Depth Market Insights:
Esketamine Market Industry Drivers: What’s Behind The Revenue Growth?
The anticipated expansion of the esketamine market over the next few years is largely attributed to the growing occurrence of treatment-resistant depression (TRD). TRD is defined as a form of depression that fails to respond even after trials of at least two distinct antidepressant drugs administered in appropriate dosages for an adequate period. The rise in TRD cases stems from the inadequate effectiveness of traditional antidepressants, resulting in extended and recurring depressive states. Esketamine offers assistance for TRD by utilizing a rapid-onset mechanism that targets NMDA receptors, thereby providing relief to individuals unresponsive to conventional antidepressant therapies. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments. Consequently, the escalating occurrence of treatment-resistant depression is serving as a key driver for the growth of the esketamine market.
Esketamine Market Segment Landscape And Growth Outlook
The esketamine market covered in this report is segmented –
1) By Formulation Type: Nasal Spray, Injectable Form
2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior
3) By Patient Type: Adult Patients
4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics
5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy
2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine
#Esketamine Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies within the esketamine market are focusing on developing advanced treatment solutions like monotherapy, aiming to improve depressive symptom relief beyond placebo effects. Monotherapy refers to managing a disease or medical condition using a single drug or treatment, rather than multiple combined therapies. For instance, in January 2025, US-based pharmaceutical company Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Clinical trials supported this approval, demonstrating SPRAVATO’s rapid ability to alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough offers a crucial option for approximately 30% of individuals unresponsive to traditional antidepressants, removing the need for concurrent oral medications. Although SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This achievement represents a significant advancement in TRD treatment, providing renewed hope for better patient outcomes.
Esketamine Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.
View The Full Esketamine Market Report:
Esketamine Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
